TrialNet ATG-GCSF New Onset Study
Study Name: Effects of Low Dose ATG (Thymoglobulin®) Used Alone or in Combination with GCSF (Neulasta®) in New Onset Diabetes
Principal Investigator: Michael Haller, M.D. 352-273-9264
Coordinator: Miriam Cintron 352-273-5580
or Main Number 352-294-5760
What is the ATG-GCSF Study?
TrialNet researchers at UF are testing whether low dose ATG used alone or in combination with GCSF will help people newly diagnosed with type 1 diabetes to continue to make some of their own insulin.
In the study, TrialNet will compare the progression of diabetes in three groups of people:
- One group will get infusions of low dose ATG and injections of GCSF.
- Another group will get infusions of low dose ATG and injections of placebo (a substance that looks like the study drug but contains no active drug).
- A third group will get placebo infusions and placebo injections (substances that look like the study drugs, but contain no active drugs).
Who can be in the ATG-GCSF Study?
You can be screened for the ATG-GCSF study if:
- You are 12 to 45 years old,
- You were diagnosed with type 1 diabetes less than 3 months ago.
If you are not eligible for this study, there may be other studies for people newly diagnosed with type 1 diabetes.
Read article published by JDRF
JDRF – New Onset Type 1 Diabetes Study
Closed to Recruitment